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PEETING HIGHLIGHTS
ighlights of the 2004 Scientific Sessions
f the Heart Failure Society of America,
oronto, Canada, September 12 to 15, 2004
eter Liu, MD,* Marvin A. Konstam, MD,† Thomas Force, MD‡
oronto, Canada; and Boston, Massachusetts
The annual scientific meeting of the Heart Failure Society of American (HFSA) brings
together cardiologists, surgeons, nurses, and allied health care workers who are interested in
improving the diagnosis, treatment, quality of life, and survival of patients affected by heart
failure. The meeting integrates the best of basic advances with clinical trials and outcomes
observations in a single seamless forum. The meeting in Toronto, Canada, attracted close to
3,000 attendees. (J Am Coll Cardiol 2005;45:617–25) © 2005 by the American College of
ublished by Elsevier Inc. doi:10.1016/j.jacc.2004.11.059Cardiology Foundation
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fhe goals of the Heart Failure Society of America (HFSA)
re to improve the diagnosis, treatment, quality of life, and
urvival of patients with heart failure (HF). One critical
nitiative was to establish an annual meeting to bring
ogether basic scientists, clinical scientists, clinicians, nurses,
nd allied health professionals to discuss recent advances in
he field in a format that fosters an exchange of ideas among
hese groups and encourages viewing HF from a transla-
ional medicine point of view. This is a report of some of the
ighlights of that meeting, the 8th Annual Scientific
essions.
PENING SESSION—HEART FAILURE 2004:
INDOW INTO THE FUTURE
arvin Konstam (President of the HFSA from 2002 to
004; Tufts-New England Medical Center, Boston, Mas-
achusetts) addressed the challenges facing the academic
edical center amidst changing times. This is particularly
ith reference to providing exemplary care for patients with
F in the academic milieu. Historically, academic medical
enters have been bound by a “social contract” to provide
xcellent medical care, advance new knowledge, and train
uture physicians on behalf of the society. However, this has
ecome economically difficult to sustain, with repeated
eductions in government funding. Treating patients with
F poses an additional challenge as the disease entity
rosses many traditional academic boundaries including
edicine, surgery, and allied health disciplines.
Unfortunately, the incidence of HF has increased by
From the *Heart & Stroke/Richard Lewar Centre of Excellence, University of
oronto, and Division of Cardiology, Toronto General Hospital, University Health
etwork, Toronto, Canada; and the †Division of Cardiology, and ‡Cardiomyocyte
iology Laboratory of the Molecular Cardiology Research Institute, Tufts-New
ngland Medical Center and Tufts University School of Medicine, Boston,
assachusetts. Dr. Force is an Established Investigator of the American Heart
ssociation. Dr. Liu holds the Heart & Stroke/Polo Chair Professor of Medicine andp
hysiology at the University Health Network, University of Toronto.
Manuscript received November 3, 2004, accepted November 24, 2004.55% in the last decade, and costs have escalated to $13
illion per year for hospitalization in the U.S. alone, and
roportionally in Canada. Paradoxically, HF is a worthwhile
rogram to undertake in academic centers. The therapy for
F is becoming increasingly complex, costly, and difficult to
dminister. Academic centers can offer this special compe-
ency and train future experts in the field while using a
ystem-based approach to disease management. High-
uality care also brings high-quality diagnostics and thera-
eutic procedures. These, in turn, help to finance the
perations necessary to maintain this complex program.
hus, focusing on HF allows the academic center to “do
ell, while doing good.”
Gerald Dorn (University of Cincinnati, Cincinnati,
hio) addressed “Innovations for Tomorrow” by first look-
ng back at centuries of HF care. Heart failure, or “dropsy,”
as first characterized by the Greek physicians as edema and
allor, and Galen initially coined the “humoral theory” of
edicine. Neurohormonal activation, including adrenergic
eceptor activation, of course has since redefined the therapy
or HF, but not all patients will benefit. Genetic single
ucleotide polymorphisms that influence the activities of,
or example, the alpha- and beta-adrenergic receptors, can
odify susceptibilities to the disease. For example, the
eta1-receptor polymorphism of beta1-Ser49 leads to beta-
eceptor down-regulation, and patients have a good five-
ear survival. On the other hand, patients with beta1-
rg389 and alpha2c-Del322–325 have much worse
utcomes, paving the way for the exciting potential of a new
pproach for the treatment and management of patients
ith HF in the future.
Jay Cohn (University of Minnesota, Minneapolis, Min-
esota) addressed the importance of HF prevention: “Why
et the Heart Fail at All?” To deal effectively with the
urden of symptomatic HF, we need to identify the risk
actors leading to left ventricular (LV) remodeling, and to
revent HF altogether. At the University of Minnesota, Dr.
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HFSA 2004 Meeting Highlights February 15, 2005:617–25ohn has applied a Rasmussen score (including electrocar-
iogram, echocardiography, and brain natriuretic peptide, in
ddition to parameters such as pulse pressure, vascular
ompliance, exercise blood pressure response, and mi-
roalbuminuria) to assess risk for LV remodeling; this score
ppears to be better than the Framingham score in predict-
ng HF. The hope is that earlier intervention can lead to
eductions in the slope of progressive remodeling, HF, and
eaths. The challenge, of course, is who should pay for the
creening, who should do the screening, and ultimately how
o we implement the preventive measures?
Bruce McManus (University of British Columbia, Van-
ouver, British Columbia, Canada) addressed the challenges
f knowledge creation to knowledge translation in HF
esearch. The Canadian HF investigators have identified
everal priority areas of research, including key mechanisms
eading to HF, diagnostic and prognostic markers, novel
harmacologic, non-pharmacologic, and cell-based treat-
ent strategies, and new paradigms of health delivery and
ealth policies. As a result, there is a systematic organization
f basic science discovery teams, as well as clinical research
etworks. The national health information database has also
een organized to produce a Canadian outcomes map, as a
ink to organize health delivery priorities. An equal empha-
is has been placed on knowledge translation. That is,
ranslating scientific knowledge gained into benefits to
atients and society as a whole. The ability to evaluate
uality of care and barriers to dissemination of knowledge
nd changing behaviors and outcomes are also priorities of
esearch at the Canadian Institutes of Health Research.
his has formed the impetus to register the outcomes of all
linical trials, to rapidly publish results, and to understand
he science of persuasion and interaction with patients. This
ill ultimately benefit both patients with HF and the
edical community at large.
YMPOSIUM ON CELL-BASED
HERAPIES FOR CARDIAC REGENERATION
n Sunday afternoon, a symposium was held for scientists
ith an interest in cell-based therapies. It drew a large
umber of individuals interested in learning more about the
urrent research in cell-based therapies for cardiac regener-
tion.
Amy Wagers (Joslin Diabetes Center, Boston, Massa-
husetts) opened the session by presenting data that strongly
uggest that adult bone marrow cells cannot serve as a
Abbreviations and Acronyms
EPC  endothelial progenitor cell
HF  heart failure
HFSA  Heart Failure Society of America
LV  left ventricular
LVEF  left ventricular ejection fractionignificant reservoir for cardiac precursor cells, and that heither these bone marrow cells, nor circulating cells can
egenerate myocardium in the post-ischemic heart.
Michael Schneider (Baylor College of Medicine, Hous-
on, Texas) discussed the loss of the telomeres in the heart
n HF, and how Sca-1 cells may restore the telomerase
ctivity. Stem cells that are Sca-1 express high levels of
elomerase activity, and these cells home to the infarcted
yocardium, and can expresses cardiac differentiation
arkers such as serum response factor, GATA-4, and
yocyte enhancer factor (MEF)-2C. Cardiac Sca-1 cells
epresent 25% of the cells in the border zone of an infarct,
nd another 25% fuse with local surviving cells. The BMP
athway is likely important in the differentiation of cardiac
ca-1 cells, likely mediated via Smads or the TAK1
ascade.
Annarosa Leri (New York Medical College, Valhalla,
ew York) discussed the role of c-kit cells in the myocar-
ium as cardiac progenitor cells, as documented both in vivo
nd in vitro. Cardiac niches for these cells are more
umerous in the atria and apex in which cardiac primitive
ells are surrounded by fibronectin. Cardiac c-kit and/or
DR1 progenitor cells express c-met (hepatocyte growth
actor receptor) and insulin-like growth factor-1R. Local
njections of insulin-like growth factor-1 and hepatocyte
rowth factor promote the translocation (and proliferation)
f cardiac progenitor cells from their site of storage to the
njured area. In the regenerated myocardium after infarc-
ion, labeled progenitor cells can be recognized and show
-kit and MDR1 together with markers of cardiac and
yocyte commitment (GATA4 and MEF2C). Moreover,
hey form coronary vessels, capillaries, and resistance arte-
ioles. These cells have a specific integrin phenotype that
llows them to translocate through the interstitium by
inding to fibronectin.
Stephanie Dimmler (University of Frankfurt, Frankfurt,
ermany) updated the audience on the role of endothelial
rogenitor cells (EPCs) in vascular repair and vasculogen-
sis. Factors such as granulocyte colony-stimulating factor,
ascular endothelial growth factor, angiopoietin-2, statins,
eroxisome proliferator-activated receptor agonists, and ex-
rcise all mobilize EPCs and are thus vasculoprotective.
nterestingly, erythropoietin, which can stimulate pro-
uction of bone marrow cells and EPCs, increases angio-
enesis and is cardioprotective. The signals that can regulate
PC mobilization are now clearer. Granulocyte colony-
timulating factor can activate proteases including elastase,
athepsin, and matrix metalloproteinase-2, and vascular
ndothelial growth factor activates matrix metalloproteinase-9,
leaves stem cell factor, which then mobilizes c-kit cells
rom the bone marrow. On the other hand, endothelial
itric oxide synthase is also important in the bone marrow
o mobilize EPCs, and nitric oxide may be important
irectly for the maintenance of the stem cell population.
Victor Dzau (Duke University, Durham, North Carolina)
eported that transplanted mesenchymal stem cells, which
ave been transduced with an adenovirus encoding the
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February 15, 2005:617–25 HFSA 2004 Meeting Highlightsro-survival protein kinase, Akt, are able to persist in the
yocardium, reducing infarct size, and restoring function
lmost to normal. These mesenchymal stem cells express
ardiac markers and are able to reduce inflammation and
ypertrophy. There is evidence of some cell fusion in the
eri-infarct zone, but fusion frequency is very low and
annot explain the efficacy of the therapy. This suggests
nstead that paracrine effects from the transduced cells may
ndeed be important. Indeed, conditioned medium of Akt-
esenchymal stem cells confers cytoprotective effects and
an protect myocytes from hypoxia-induced damage.
Helmut Drexler (Medical University of Hannover, Han-
over, Germany) updated the audience on the mechanistic
nsights into the Bone Marrow Transfer to Enhance ST-
levation Infarct Regeneration (BOOST) trial. Although
he left ventricular ejection fraction (LVEF) improved
ignificantly in the bone marrow cell transfer group, there
as no difference in infarct size by magnetic resonance
maging delayed enhancement or end-diastolic volume.
ore recent studies with labeled bone marrow cells incor-
orating 18F-deoxyglucose and followed with positron
mission tomography showed that the majority of cells are
n the spleen and liver, with no uptake in the brain, and only
% to 4% are in the heart. Thus, the mechanism of
mprovement in LVEF is unclear at present.
Andreas Zeiher (University of Frankfurt, Frankfurt, Ger-
any) conducted the original TOPCARE-AMI study by
nfusing bone marrow cells in 59 patients after myocardial
nfarction. Clinical follow-up indicated that the LVEF
ncreased by 6% in the initial four months, and increased by
nother 5% in the next eight months. The LV mass also
ecreased over the first four months, suggesting an attenu-
tion of LV hypertrophy with improvement in infarct
emodeling. There was also a significant decrease in coro-
ary vascular resistance by Doppler wire measurements.
his study is being followed by the ongoing REPAIR-AMI
rial conducted in a double-blinded randomized fashion.
Donald Orlic (National Institutes of Health, Bethesda,
aryland) has evaluated the effect of cytokines on stem cell
obilization. He has observed that the same stem cell that
epopulates the marrow is also the one that regenerates the
yocardium, particularly the linc-kit cells. The majority
f the cells are endothelial cells, with very few myocytes, and
poptosis occurred within 3 to 5 h of implantation. Day 5
fter infarction appears to be the maximal for cell repopu-
ation, and studies from a variety of primate models showed
hat there is some angiogenesis, but very little myogenesis.
HEMOTHERAPY-INDUCED HF
n this important session chaired by Lynne Warner Steven-
on (Brigham and Women’s Hospital, Boston, Massachu-
etts) and Douglas Sawyer (Boston University, Boston,
assachusetts), the increasing problem of HF in patients
aking chemotherapeutic agents for cancers was addressed.
he first agents discussed were the anthracyclines, including toxorubicin, and in a series of experiments carried out over
he last few years in cultured cardiomyocytes and experi-
ental animals, Mona Nemer (Institut de Recherches
liniques de Montreal, Montreal, Canada) has identified
oxorubicin-induced down regulation of GATA4, a tran-
cription factor known to play critical roles in cardiac
evelopment and hypertrophy, as a major mechanism un-
erlying doxorubicin-induced cardiotoxicity. She then went
n to demonstrate that infusion of the alpha-adrenergic
gent, phenylephrine, prevented doxorubicin-induced car-
iotoxicity, apparently by preventing the down-regulation
f GATA4. The potential implications of these findings for
he treatment of patients receiving anthracyclines, as well as
f the use of alpha-adrenergic blockers in these patients,
ere discussed.
Thomas Suter (University Hospital, Bern, Switzerland)
hen discussed traztusumab (Herceptin), another agent
nown to induce heart failure. Traztusumab is a monoclonal
ntibody that blocks activation of a tyrosine kinase receptor
alled ErbB2, which is a member of the epidermal growth
actor (EGF) family and is amplified in about 20% of breast
ancers. Herceptin improves survival in these patients but at
he expense of HF, which is particularly prevalent when
sed in combination with doxorubicin (28% of patients
evelop some degree of HF and in 16% of patients it is New
ork Heart Association functional class III or IV). In
xperimental animals, doxorubicin leads to myofiber disar-
ay and this is made worse by traztusumab. In contrast,
hen an activator of the ErbB2 receptor (neuregulin) is
iven together with doxorubicin, myofiber disarray is re-
uced. The mechanism appears to be that the ErbB2
eceptor, acting via the ERK-MAPK pathway, leads to the
nduction of anti-oxidant enzymes that negate the adverse
xidant properties of doxorubicin. The mechanism of the
oxorubicin-induced myofiber disarray may be calpain-
nduced destruction of the sarcomeric protein titin. Of note,
lthough the HF is usually reversible with discontinuation
f the drugs, it re-appears with re-challenge and thus limits
he amount of drug that can be given. Although not fully
tudied, it appears that cardiotoxicity with taxol plus her-
eptin is probably less than with doxorubicin plus herceptin.
inally, combining inhibitors of both ErbB1 (EGF-
eceptor) and ErbB2 also leads to cardiotoxicity, whereas
rbB1 inhibition alone (an example is Iressa, which has
een approved for lung cancer) does not appear to.
Jean-Bernard Durand (M. D. Anderson Cancer Center,
ouston, Texas) then outlined concerns about the potential
ardiotoxicity of imatinib (Gleevec), a drug that targets the
ncogenic tyrosine kinase, Bcr-Abl, deregulation of which is
ausal in chronic myelogenous leukemia. This drug has
evolutionized the treatment of patients with chronic my-
logenous leukemia. Although the risk cannot be quantified
t this time, it does appear that the agent can be cardiotoxic
nd lead to HF in some patients. In addition, Dr. Durand
howed the large number of chemotherapeutic agents that
arget tyrosine kinases (other than ErbB2, the EGF-
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HFSA 2004 Meeting Highlights February 15, 2005:617–25eceptor, and Bcr-Abl) that are now in clinical trials, and
uggested that these need to be watched very carefully for
ardiotoxicity. This sentiment was echoed by Daniel Leni-
an (M. D. Anderson Cancer Center, Houston, Texas),
ho also addressed the question of whether one could
evelop guidelines for the treatment of patients with
hemo-induced HF. He outlined the striking beneficial
ffects of angiotensin-converting enzyme inhibition in some
orms of chemo-induced HF, including herceptin-induced
ailure. Finally, all speakers and moderators issued a plea for
reater awareness on the part of the oncology community of
his problem, both for the treatment of patients receiving
nown or suspected cardiotoxic agents as well as for the
esign of future clinical trials with new agents, and sug-
ested that this be a priority of the HFSA.
ITOCHONDRIA AS SIGNALING
LATFORMS IN MYOCARDIAL DISEASES
his session examined the role of mitochondria in both
etabolism/energy generation and in the balance of cell
urvival/death. Jeffery Molkentin (University of Cincinnati,
incinnati, Ohio) described his studies on regulation of the
pening of the mitochondrial membrane pore, a process
hat allows the release of cytochrome c and pushes the cell
oward apoptosis. One protein that associates with the
omponents of the pore is cyclophiin D, the function of
hich in regulating pore opening has not been clear.
olkentin created a mouse with the cyclophilin D gene
nocked out and found that the mitochondria of these mice
ere resistant to pore opening. That this is likely very
elevant in vivo is suggested by the finding that the
nockout had a 40% reduction in infarct size in an ischemia/
eperfusion injury model. This makes cyclophilin D a
otential therapeutic target to reduce ischemic (and possibly
ther forms) of injury. Peipei Ping (UCLA, Los Angeles,
alifornia) followed this up with her observations on the
rotection against pore opening provided by a particular
soform of protein kinase c-epsilon, also a potential thera-
eutic target.
Daniel Kelly (Washington University, St. Louis, Mis-
ouri) then discussed the role of PGC-1-alpha (PPAR-
amma- co-activator-1-alpha) in mitochondrial function.
he PGC-1-alpha is a co-activator of gene induction for
PARs (the targets of thiazolidenediones), and plays a
ritical role in the expression of all myocardial mitochon-
rial genes responsible for the uptake and oxidation of fatty
cids, and in addition is a co-activator for nuclear respiratory
actors 1 and 2 which lead to the activation of replication of
itochondrial genes necessary for oxidative phosphoryla-
ion. Thus PGC-1-alpha can be viewed as a factor necessary
or mitochondrial maturation. The PGC-1-alpha knockout
ice have a relatively subtle phenotype in that heart and
keletal muscle size is only slightly decreased. However,
TP-synthesizing capacity of mitochondria from the KO is
educed, the mice have an abnormal chronotropic response, cnd LV fractional shortening is decreased. In contrast,
hronic activation of PGC-1-alpha leads to a dilated car-
iomyopathy.
THE TWO FACES OF POSITIVE INOTROPY”
his session discussed how factors that cause increased
ardiac contractility can also cause myocyte death. Physio-
ogic hemodynamic stress (typically exercise) is intermittent
nd the associated increase in cardiac contractility involves
ctivation of the sympathetic nervous system and increased
ellular calcium concentration. In contrast, persistent patho-
ogic hemodynamic stress (e.g., pressure load from hyper-
ension or valvular disease) involves long-term (days to
ears) elevation in cardiac contractility. Data presented by
teve Houser (Temple University, Philadelphia, Pennsylva-
ia) showed that persistent elevations in Ca2 influx can
ead to Ca2 overload which eventually activates apoptosis.
ui-Ping Xiao (National Institute on Aging, Bethesda,
aryland) then showed that persistent activation of beta-1-
drenergic receptors, which also leads to persistently high Ca2
oncentrations, activates calcium/calmodulin-dependent ki-
ases (CaM kinases) which can activate mitochondrial
eath pathways. These studies suggest that pathologies such
s hypertension that can induce persistent activation of
drenergic signaling and elevations in myocyte calcium
oncentration can induce myocyte apoptosis. The subse-
uent reduction in the number of viable myocytes may be a
ritical factor that precipitates cardiac decompensation and
F.
ROTEIN REMODELING IN HF
athologic remodeling in failing hearts involves extensive
nd highly regulated changes in cellular protein content and
unction, including targeted protein cleavage and degrada-
ion carried out by specific proteases. In this session, four
resentations covered different aspects of protease function
nd their regulation in the process of apoptotic cell death
Richard Kitsis, Albert Einstein College of Medicine,
ronx, New York), gene regulation (Robert Schwartz,
aylor College of Medicine, Houston, Texas), skeletal
uscle atrophy (David Glass, Regeneron Pharmaceuticals,
nc., Tarrytown, New York), and myocardial remodeling
Yibin Wang, UCLA, Los Angeles, California). Dr. Kitsis
resented new findings that a protein named ARC (apo-
tosis with caspase recruitment domain) functioned as a
otent repressor of myocyte apoptosis by inhibiting both
itochondria-dependent and receptor (tumor necrosis fac-
or and Fas)-mediated apoptotic pathways and may serve as
novel tool to protect myocytes from ischemic injury and
eath. On the other hand, Dr. Schwartz presented data
emonstrating that caspase activity in human failing hearts
ediated specific cleavage of serum response factor, a
ranscription factor regulating expression of a number of
ritical genes. Thus, caspases contribute significantly to the
hanges in the gene expression profile of patients with heart
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February 15, 2005:617–25 HFSA 2004 Meeting Highlightsailure. Dr. Glass demonstrated the power of using genomic
pproaches in signaling studies on skeletal muscle atrophy
nd hypertrophy by presenting his findings that two novel
biquitin ligases, MAFbx and MuRF1, are critical compo-
ents in the process of muscle degeneration. The intricate
egulation of these proteins by protective pathways, such as
GF-1/PI3Kinase/Akt, provided both a molecular mecha-
ism in muscle remodeling and a new venue for targeted
herapy. Finally, Dr. Wang presented data from both in
itro and in vivo studies to illustrate the important contri-
ution of stress-activated MAP kinases (JNKs and p38-
APKs) to specific aspects of cardiac remodeling, includ-
ng the loss of inter-cellular communication through gap
unctions and increased fibrosis in extracellular matrix re-
odeling. In short, the session illustrated the important role
f proteases and their regulation in muscle remodeling and
ysfunction. It is clear that a better understanding of the
nderlying regulatory mechanisms of protease expression
nd activity may lead to new therapeutic targets for HF.
EBATES
hould mortality remain the major primary end point for
F trials? Christopher O’Connor (Duke University,
urham, North Carolina) argued the “pro” point of view,
voking the current acceptance of “life-saving therapy” for
ardiovascular patients to include aspirin, angiotensin-
onverting enzyme inhibitors, beta-blockers and reperfusion
herapy. On the other hand, agents such as flolan and
esnarinone had attractive mechanisms but did not protect
he patients at the bedside, as risk and benefit of unintended
argets can only be determined from large trials. Despite the
act that digoxin reduces hospitalizations, its use has de-
lined due to a lack of a mortality benefit. The A-HeFT
rial (combined isosorbide dinitrate-hydralazine in African
mericans with HF) was recently stopped early mainly for
urvival benefits. Under-powered studies can be misleading,
uch as the smaller Evaluation of Losartan in the Elderly
ELITE I) (49 deaths in 722 patients) and the phase II
esnarinone trials (46 deaths in 477 patients). Thus, the
ortality end point in HF trials is definitive, easy to
djudicate, changes practice, and provides the best estimates
f safety.
On the other hand, Jay Cohn (University of Minnesota,
inneapolis, Minnesota) argued the “con” side by stating
hat mortality is an insensitive and non-specific measure for
F therapy evaluation. Deaths affect only a small minority
f patients in a trial. Deaths provide no mechanistic insights
nto the treatment effect, and do not provide guidance to
ndividualized therapy. Mortality end points mandate study
f patients with advanced disease, whereas the greatest
pportunity to halt progression comes from treatment
uring earlier stages. Non-mortality end points are more
ensitive and specific to the disease, such as HF hospital-
zation and LV structural remodeling. Future trials should
ncorporate end points such as quality of life, progression of bisease, and homogenous subgroups to gain mechanistic
nsights.
hould the results of the implantable cardioverter-
efibrillator (ICD) trials be applied generally to all HF
opulations? Arthur Moss (University of Rochester,
ochester, New York) presented the “pro” view, stating that
ulticenter Automatic Defibrillator Implantation Trial
MADIT I), MADIT II, Sudden Cardiac Death in Heart
ailure Trial (SCD-HeFT), and Comparison of medical
herapy, resynchronization, and defibrillation therapies in
eart failure trial (COMPANION) all show significant
eduction in mortality in HF patients. Pooled analysis does
how that QRS duration is associated with progressive
egrees of protection, in that for QRS 0.12 s, the hazard
atio is 0.76; for 0.12  QRS 0.15 s, the hazard ratio is
.65; and for QRS 0.15 s, the hazard ratio is 0.37. The
bsolute risk reduction of 5% to 6% with relative risk
eduction of 25% to 35% is meaningful, as the patients were
n optimal medical therapy. But Dr. Moss agrees that not
veryone needs an ICD, particularly end-stage patients, who
ave multiple comorbidities with shortened life expectancy.
nother cohort is the low-risk patients, for example, those
ho have all of the following features: New York Heart
ssociation functional class II, QRS 0.13 s, age 72
ears, in sinus rhythm, serum creatinine 1.4 mmol/l, and
VEF 0.25, for example.
Mark Estes (Tufts-New England Medical Center, Bos-
on, Massachusetts) argued the “con” side by stating that
CD is expensive therapy that is not without risks. The ICD
enefit in HF is doubled in secondary prevention compared
ith primary prevention. The patients who benefit the most
re those with ischemic cardiomyopathies with LVEF
30% or 35%. This does not include patients with higher
jection fractions or other forms of HF. Several trials
ncluding The Coronary Artery Bypass Graft Patch Trial
CABG-Patch) showed that an ICD does not influence
on-arrhythmic deaths, and total mortality may not be
ifferent. Finally, one in three patients with an ICD will
xperience adverse effects such as inappropriate shocks,
nfection, or DDD or VVI pacing that has adverse hemo-
ynamic effects for the compromised ventricle. Thus, selec-
ive use of ICD is essential.
ANOTECHNOLOGIES IN MEDICINE
n innovative session chaired by Denis Buxton (NHLBI,
ethesda, Maryland) addressed the question: “The New
anotechnologies: Where Will They Take Us?” Drs. Bux-
on, Gregory Lanza (Washington University, St. Louis,
issouri), and Patrick Stayton (University of Washington,
eattle, Washington) outlined applications of these tech-
ologies that exist at the micrometer and submicrometer
evel (i.e., smaller than the size of a red blood cell). Dr.
anza discussed the application of these technologies to
maging pathologic processes and to drug delivery that can
e targeted to individual cells or pathologies. He showed
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HFSA 2004 Meeting Highlights February 15, 2005:617–25xamples of magnetic resonance imaging of intravascular
hrombi utilizing a magnetic resonance imaging agent
ackaged inside a liquid perfluorocarbon nanoparticle emul-
ion. The nanoparticles can be targeted specifically to the
hrombus via an antibody expressed on the surface of the
anoparticle directed against cross-linked fibrin, allowing
ven relatively small thrombi to be imaged. He also dem-
nstrated the ability to image angiogenesis in early stages of
therosclerosis. This employed injection of paramagnetic
anoparticles targeted by an antibody to v3 integrins,
embrane proteins that are highly expressed in areas of
eovascularization. He then demonstrated that related tech-
ologies could allow targeted drug delivery selectively to
reas of disease using “contact-facilitated drug delivery.”
ith this approach, a lipophilic drug is packaged as part of
he surface of a liposome that contains a targeting molecule
e.g., an antibody) displayed on the surface of the liposome.
he drug is not released until the liposome binds to the
arget cell. When this occurs, there is exchange of lipid from
he liposome with that of the cell membrane, allowing the
rug to selectively enter the cell. This targeting allows the
elivery of high concentrations of a drug to a desired cell
ype, thus greatly reducing systemic exposure of the drug,
nd thereby limiting toxicity. Dr. Stayton then explored
pproaches to tissue engineering of the heart and demon-
trated that cultured cardiomyocytes could be induced to
rient themselves in an orderly fashion on parallel micro-
trips of laminin-coated elastomeric polyurethane films that
re biodegradable. This parallel alignment allowed a much
ore ordered and effective contraction than one could
chieve in the absence of this ordering. He went on to
iscuss approaches that could be used to modify biomate-
ials to control vascularization around tissue-engineered
egeneration materials, and to regulate the foreign body
eaction to biomaterials. The use of controlled release of
roteins and nucleic acids from hydrogel matrices will
ermit control of vascularization, an essential component of
roducing viable tissue repair. Delivery of anti-
nflammatory mediators, such as antisense and ribonucleic
cid interference therapeutics, that inactivate macrophage
ignaling targets or inflammatory cytokines, may help to
ontrol harmful inflammatory processes. Although still
ome time away from clinical applications, these studies
emonstrated the potential of transplantation of tissue-
ngineered cardiomyocytes for repairing failing hearts and
he need for an integrated strategy to control inflammation
nd vascularization in addition to providing new myocytes.
HE INTERFACE OF ACADEMIA AND
NDUSTRY IN HF THERAPEUTIC DEVELOPMENT
n a noontime “How To” session, representatives from the
iotechnology and pharmaceutical industry (Seigo Izumo,
ovartis Institutes for Biomedical Research, Cambridge,
assachusetts; Ted McCluskey, Scios, Fremont, Califor-
ia; Ralph Kelly, Genzyme Corporation, Framingham, eassachusetts) discussed impediments to the development
f novel therapies specifically for the HF patient and
otential approaches to breaking down those impediments.
rs. Izumo and McCluskey outlined several problems: 1)
he relatively small size of the HF market (in the U.S. it is
10% of the hypertension market and of the statin market);
) this is compared with the very high cost of bringing a
ovel therapeutic to market in terms of years (10) and
xpense ($100 million); 3) in addition, there are extremely
trict requirements for efficacy and safety for cardiovascular
rugs; this is in contrast to the relatively lenient require-
ents for novel therapies to treat cancers, despite the fact
hat the prognosis of many patients with HF is worse than
hat for many cancers; and 4) finally, the requirement for a
ovel therapeutic to demonstrate efficacy when added to
onventional treatments with previously demonstrated effi-
acy, which now includes 3 agents, is perceived as likely
eing difficult to achieve. All of these impediments have led
any companies to abandon their HF initiatives, despite
he steadily rising incidence of HF in the developed world.
pproaches to address these difficult problems were sug-
ested to include advocacy by the patients and their families,
s well as open forums involving physician/nurse organiza-
ions (e.g., HFSA, American College of Cardiology, Amer-
can Heart Association), industry, and the Food and Drug
dministration such as occurred in an earlier session chaired
y Uri Elkayam (USC, Los Angeles, California) and Cesare
rlandi (Otsuka Maryland Research Institute, Rockville,
aryland) that focused on drug development for acutely
ecompensated HF. Finally, Dr. Kelly described novel
herapeutic approaches not involving pharmacologic agents,
pecifically gene therapy utilizing adenovirus-mediated gene
ransfer. An ongoing trial treating patients with ischemic
imbs, in which an adenovirus encoding the transcription
actor HIF-1-alpha is injected into the ischemic zone,
ttempts to induce angiogenesis in the ischemic region. In
ddition, he discussed potential future applications in HF
targeting the beta-adrenergic system). However, Dr. Kelly
epeatedly underlined the critical importance of stringent
afety in any future gene therapy trials.
ENETICS AND HF
he interface of genetics and clinical management was
ddressed in two symposia; the first focused on lessons
erived from investigations in familial syndromes. In the
amilial session, Luisa Mestroni (University of Colorado,
urora, Colorado) summarized the role of genotype in
efining the risk of sudden death for subjects with hyper-
rophic cardiomyopathy (HCM). Molecular analysis has
efined HCM as primarily a disorder of the sarcomere, as
utations of multiple contractile proteins result in the
linical phenotype. The risk of sudden death differs mark-
dly between pedigrees, and much of this clinical heteroge-
eity reflects differences in the specific mutations. It is
xpected that the clinical evaluation of arrhythmic risk for
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February 15, 2005:617–25 HFSA 2004 Meeting Highlightsubjects with HCM will soon include genotype assessment,
owever this form of evaluation remains a research tool
hich is not yet clinically available. In the key-note address
or this session, Jeffrey Towbin (Texas Children’s Hospital,
ouston, Texas) reviewed the current understanding based
n molecular analysis of the structural basis of dilated
ardiomyopathy (DCM) as a disorder of the cytoskeleton.
he clinical application of genomics to clinical management
or subjects with DCM is still at an early stage of develop-
ent.
A second session was devoted to clinical applications of
opulation genetics. Variations in genetic background affect
he degree of neurohormonal activation and, therefore,
nfluence clinical outcomes. Dennis McNamara (University
f Pittsburgh, Pittsburgh, Pennsylvania) presented data
rom outcome studies at the University of Pittsburgh that
he 30% of HF subjects who are homozygous for the ACE
allele have poorer survival. This genetic risk was markedly
iminished by therapy with either high-dose angiotensin-
onverting enzyme inhibitors or beta-blockers. Heart failure
s polygenic and polymorphisms of the beta-adrenergic
eceptors and endothelial nitric oxide synthase also influence
linical outcomes and the effectiveness of pharmacologic
herapy. Barry London (University of Pittsburgh, Pitts-
urgh, Pennsylvania) broadened the discussion to include
ot only “pharmacogenomics” but also “device-genomics”
nd presented population data on how variation in Herg, a
ene that encodes a potassium channel which is responsible
or long QT in some families, can increase the risk of
udden death. Current investigations are focused on devel-
ping a genetic profile of arrhythmic risk to determine
ubjects who receive maximal benefit from prophylatic
CDs. Analysis from the Framingham study presented by
hristopher O’Donnell (NHLBI, Framingham, Massachu-
etts) demonstrates how haplotype analysis allows determi-
ation of the key genetic loci determining such clinical
henotypes as LV hypertrophy.
HE ROLE OF EXERCISE IN HF
ndrew Coats (University of Sydney, Sydney, Australia)
egan the session by reminding the audience of the poor
orrelation between LVEF and peak oxygen consumption
uring exercise in HF. Exercise training improves exercise
uration, cardiac output, myocardial perfusion and LVEF.
echanistically, this is associated with improvements in
ndothelial dysfunction, skeletal metabolism, mitochondrial
xidative capacity, and enhances baroreflex control. Meta-
nalysis also suggested improvement in survival and de-
reased hospital admission.
Leslie Leinwand (University of Colorado, Boulder, Col-
rado) discussed the basic mechanisms of cardiac remodel-
ng in the presence of exercise. Interestingly there appears to
e a gender difference in the mouse model, in that female
ice are more active, and have greater cardiac hypertrophy,
ith a unique pattern of gene expression changes. The (SK-3 activation appears to be specific in inhibiting the
athologic hypertrophy seen in banding-induced pressure
verload, but not essential for exercise-induced hypertrophy.
Robert McKelvie (McMaster University, Hamilton, On-
ario, Canada) discussed the various exercise training pro-
ocols. Whether exercise training is done with a cycle
rgometer or a treadmill, most patients show an increase in
O2 of 14% to 25%. An aerobic training protocol is most
ommonly used, aiming for 50% to 80% of peak perfor-
ance, 3 to 5 times per week, at 20 to 60 min per session.
ore recently, the role of resistance training at 40% to 70%
f peak strength, incorporating 10 to 15 repetitions up to a
aximum of 3 sets, have become more recognized. Interval
xercise training also increases endurance and muscle
trength.
Ileaña Pina (Case Western Reserve, Cleveland, Ohio)
resented the rationale for the HF ACTION trial, attempt-
ng to determine the role of exercise training on morbidity
nd mortality. The trial is powered to demonstrate that
xercise training can lower death and hospitalization by
0%. The inclusion criteria will include New York Heart
ssociation functional class II to IV HF patients with
VEF 35% on stable medications for 6 weeks. The
atients will be randomized to intervention consisting of 36
xercise training sessions, and clinical assessment and car-
iopulmonary testing at three months and yearly during
ollow-up.
LINICAL TRIALS UPDATE
ral Enoximone in Inotrope-Dependent Subjects
EMOTE). Arthur Feldman (Thomas Jefferson Univer-
ity, Philadelphia, Pennsylvania) presented this trial to
etermine if low-dose enoximone can permit weaning of
dvanced HF patients from intravenous inotropic therapy.
he trial enrolled 201 New York Heart Association func-
ional class III or IV inotrope-dependent HF patients with
VEF 25% and LV end-diastolic diameter 54 mm to
noximone 25 or 50 mg po tid (n  101) or placebo. The
rimary end point of the trial was being alive and free from
ntravenous inotropes at 30 days of follow-up, and the
econdary end points were measured at later time points up
o 26 weeks. The results at 30 days showed that 51% of the
atients were alive and free of inotropes at 30 days in the
lacebo group, and 61% in the enoximone group (p 
.138). At 60 days, the percent of patients weaned off
ntravenous inotropes and alive was 30% and 49% in the
lacebo and enoximone groups, respectively (p 0.007). At
6 weeks of follow-up, there was a reduction of 32% in
erms of death, failure to wean from or re-initiation of
ntravenous inotropes in the enoximone group compared
ith placebo (p  0.04), and the number of days on
ntravenous inotropes was decreased by 43% in the enoxi-
one group. By intention-to-treat, there were 38 deaths in
noximone group and 31 deaths in the placebo group
hazard ratio  1.27, p  NS), but in patients who had not
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HFSA 2004 Meeting Highlights February 15, 2005:617–25een withdrawn from study medication the enoximone and
lacebo deaths were 15 and 16, respectively (p  0.91).
hus, although the primary end point at 30 days was not
et, the results for longer treatment periods suggested
enefit of enoximone in the ability to wean advanced HF
atients from intravenous inotropes.
awthorn Extract Randomized Blinded HF (HERB
HF) study. Keith Aaronson (University of Michigan,
nn Arbor, Michigan) summarized this trial to evaluate the
ole of an extract of the leaves and flowers of the hawthorn
ree in patients with HF in a double-blind randomized trial.
awthorn has been shown to have mild inotropic and
asodilatory effects with low toxicity. Patients with New
ork Heart Association functional class II to III HF were
andomized to hawthorn 450 mg po bid (n  54) versus
lacebo (n  57) on standard background therapy. The
rimary end point was the distance on 6-min walk test at 3
nd 6 months of follow-up. The results showed no differ-
nce in 6-min walk test between the two groups (from 373
53 m at baseline to 379  52 m at 6 months in the
lacebo group, vs. 357  52 m at baseline to 371  89 m
t 6 months; p  0.41). The LVEF effects were nominally
avorable for the hawthorn group (35% to 33% in placebo
rm and 37% to 37% in hawthorn group; p  0.04). Patient
lobal assessment of quality of life and changes in the
innesota Living with Heart Failure Questionnaire quality
f life score were also indistinguishable between the two
roups. Thus, hawthorn did not have a measurable substan-
ial benefit on submaximal exercise capacity, LV function, or
uality of life in patients with HF.
he Warfarin and Antiplatelet Trial in Chronic Heart
ailure (WATCH). Barry Massie (UCSF, San Francisco,
alifornia) provided on update on the WATCH trial. The
ATCH trial was designed to determine the optimal
ntithrombotic therapy for patients with chronic heart
ailure who were in sinus rhythm. The WATCH trial
andomized patients to three parallel groups: open label
arfarin (target international normalized ratio 2.5 to 3.0) or
ouble-blind aspirin 162 mg or clopidogrel 75 mg. The
rimary end point was the composite of death from all
auses and non-fatal myocardial infarction and stroke. Two
rimary comparisons were planned: warfarin versus aspirin
nd clopidogrel versus aspirin, with the latter intended to
rovide indirect information as to whether aspirin has an
dverse effect in HF patients who are treated with
ngiotensin-converting enzyme inhibitors.
Although the WATCH trial was originally designed to
nroll 4,500 patients, the trial was terminated prematurely
ecause of slow recruitment. Nonetheless, with 1,587 pa-
ients with New York Heart Association functional class II
o IV congestive HF and LVEF 35% and followed for a
ean of 1.9 years (3,068 patient-years of follow-up), it is
he largest trial of antithrombotic therapy in a HF popula-
ion.
No significant differences between the three treatmentroups were observed in the primary composite end point or sn all-cause mortality. However, significant differences
merged for secondary end points. The incidence of stroke
as lower in warfarin-treated patients than either aspirin or
lopidogrel (0.7% vs. 2.1% and 2.5%, respectively); the
troke rate was significantly lower when warfarin was
ompared with the combined antiplatelet therapy groups (p
0.001). The number of patients hospitalized for worsen-
ng HF and the number of hospitalizations were 27% and
1% lower with warfarin versus aspirin (p  0.01 and p 
.001, respectively). Similar, but not statistically significant
rends toward fewer HF admissions were seen with clopi-
ogrel versus aspirin. Dr. Massie speculated that the poorer
F outcomes with aspirin may represent an adverse effect of
rostaglandin inhibition. However, he concluded that in the
bsence of significant differences in the primary end point,
hese observations should be viewed primarily as hypothesis-
enerating.
he Bone Marrow Transfer to Enhance STEMI Regener-
tion (BOOST) trial. Kai C. Wollert (University of
anover, Hanover, Germany) updated the audience on the
bjective of the study, that is to evaluate the effects of
ntracoronary autologous bone marrow cell infusions on LV
emodeling and ventricular function. Patients with acute
T-segment elevation myocardial infarction who had suc-
essful percutaneous coronary intervention with stent im-
lantation and regional LV hypokinesis, underwent mag-
etic resonance imaging to evaluate LVEF, and were
andomized to receive unselected nucleated bone marrow
ells aspirated from the iliac bone or conventional treatment
ccording to current practice guidelines. On day 5 after
ercutaneous coronary intervention, the patients random-
zed to intervention received four to five infusions of
ucleated bone marrow cells during transient balloon occlu-
ion into the infarct-related coronary artery. The primary
nd point was LVEF change at six months as determined by
agnetic resonance imaging and evaluated by two blinded
bservers. The control group had an LVEF of 51.3% at
aseline, and 52.0% at six months’ follow-up, representing a
.7% change. The cell transplantation group had a baseline
VEF of 50.0% and 56.7% at six months, or a 6.7% LVEF
hange (p  0.0026). Regional wall motion in the infarct
order zone also significantly improved in the bone marrow
ell group. Cell transfer did not significantly impact on LV
nd-diastolic volumes. No enhanced in-stent restenosis or
entricular arrhythmias were observed. However, as noted
y Dr. Drexler in the stem cell session, mechanisms of the
mprovement in LVEF are unknown at the present time.
he Beta-Blocker Evaluation of Survival Trial-Single
ucleotide Polymorphism (BEST-SNP) substudy. Ste-
hen Liggett (University of Cincinnati, Cincinnati, Ohio)
eminded the audience that the objective of this substudy
as to determine if the position 389 variant of the beta-
drenergic receptor modified the response to beta-blockers
n HF from the original Beta Blocker Evaluation of Survival
rial (BEST) cohort. Previous basic studies have demon-
trated that of the position 389 variant of BAR, the adenyl
c
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February 15, 2005:617–25 HFSA 2004 Meeting Highlightsyclase activity of Arg389 is much greater than Gly389,
uggesting hyperactivity of BAR in patients with this
olymorphism, which may be associated with a worse
rognosis. On the other hand, response to the beta-blocker,
ropranolol, was much more marked in hearts harboring the
rg389 allele. The BEST trial evaluated bucindolol in
atients with moderate to severe HF, followed for five years.
he primary end point was not met in terms of a significant
ifference in outcomes between the treated or placebo
roups. In this follow-up substudy of 1,040 patients de-
igned to determine whether there were differences in
esponse to beta-blocker between the polymorphisms, 525
atients were in the placebo arm, and 515 patients were in
he bucindolol group; Gly389 carriers were 289 in placebo,
nd 258 in the bucindolol group. The Arg389 patients who
ere treated with bucindolol had significantly improved
urvival compared with those on placebo, with a hazard ratio
f 0.62 (p  0.01). On the other hand, the Gly389 patients
id not benefit from beta-blocker therapy. Thus polymor-
hic variation at position 389 of the beta-adrenergic recep- sor may significantly influence pharmacologic response. This
epresents one of the first systematic examinations of phar-
acogenetic influences of beta-blocker therapy in HF.
cknowledgements
e are particularly grateful to Denis Buxton, Dennis
cNamara, Steve Houser, Yibin Wang, and all of the
resenters of the Opening Plenary and Clinical Trials
ession for contributing their thoughts and feedback on this
ighlights article. We are also most appreciative of the
fforts of Ms. Cheryl Yano, Executive Officer of the HFSA,
or the superb organization of the meeting and facilitation
f this Highlight publication. We thank all of the attendees
or contributing to an excellent scientific meeting that
elped to define the frontiers of HF research.
eprint requests and correspondence:Dr. Thomas Force, Tufts-
ew England Medical Center, Molecular Cardiology Research
nstitute, 750 Washington Street, Box 8486, Boston, Massachu-
etts 02111. E-mail: TForce@tufts-nemc.org.
